Key Highlights

● DOC closed at $18.80 on 9 October 2026.

● Market data consensus target is $22.10, implying about 17.6% upside.

● The analyst rating consensus is Buy.

● Mizuho, RBC, Robert W. Baird, Cantor Fitzgerald, Citigroup and Barclays all raised targets between July.

Healthpeak Properties (NYSE:DOC), a healthcare real estate investment trust and S&P 500 constituent, closed at $18.80 on Friday 9 October 2026. Analysts covering the stock set a consensus twelve-month target well above that level, though most keep a neutral rating.

What Is the Latest Analyst Price Target?

Market data shows a consensus twelve-month price target of $22.10 from 18 analysts, with a high of $24 and a low of $17. The second data set shows a higher mean of $22.95 and a median of $22 from 22 analysts, with a high of $29 and a low of $17.

The market data figure of $22.10 is the primary reference because it is consistent with recent named broker targets, which range from $21 to $24. Against the $18.80 close, it implies potential upside of about 17.6%. The second data set's mean would imply about 22.1%, and the two data sets differ on the consensus.

What Are Wall Street Analysts Saying?

Analysts are largely neutral. Market data shows four Buy ratings, fourteen Hold and no Sell, giving a consensus rating of Hold. The second data set records five Strong Buy, three Buy and fourteen Hold, which it summarises as Buy.

Most recent broker activity has been to raise targets. Mizuho lifted its target from $21 to $24 on 6 July and kept an Outperform rating. In August, RBC raised from $21 to $24 (Outperform), Robert W. Baird from $21 to $24 (Outperform), Cantor Fitzgerald from $20 to $23 (Neutral) and Citigroup from $20 to $22 (Neutral). Barclays raised from $23 to $24 on 31 August with an Equal Weight rating. The main exception was Jefferies, which trimmed its target from $22 to $21 on 15 September while reiterating Hold.

What Could Help the Stock Reach the Price Target?

A string of upward target revisions in July and August suggests analysts have become somewhat more constructive on the sector. For the share price to move towards the consensus target, investors would probably need evidence of stable occupancy, healthy rent growth and disciplined capital allocation. Lower interest rates could also improve valuations, as REITs are rate-sensitive.

What Could Prevent the Stock Reaching the Target?

The dominant Hold stance indicates that most analysts see balanced risks. Higher-for-longer interest rates, slower leasing in life science or medical office properties, rising costs or weaker tenant finances could weigh on earnings. The lowest target, $17 on both data sets, is below the current price, showing that at least one analyst sees downside.

What Should Investors Watch Next?

Investors may also watch for target changes, shifts in the ratings split and interest rate expectations.

Healthpeak's Rate-Sensitive Road to $22

Healthpeak Properties closed at $18.80 on 9 October 2026, with the market data consensus of $22.10 and the second data set's $22.95 both sitting above that level. Six brokers raised targets over the summer and only Jefferies cut, yet the lowest target on both data sets, $17, remains below the $18.80 close.